Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: zeta1961 who wrote (812)	2/14/2005 4:32:59 PM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

INGN Since the present near term uptrend started after the Jan.21-Jan.24 double bottom at the 6.50 level, the stock has continued to move up on a relatively low volume and today it was able to close only a penny below its intra-day H of 8.24 In so doing, it was able to close above its Jan.4 H of 8.24 and the next resistance is now the Jan.3 H at 8.51 <g> Of course it still has to deal with the Dec.23 H at 9.26 before it can test the Dec.9 H at 9.81 (Both of those Hs were made on expanding volume. Dec.9 was the day of the last up-gap and the volume of 7,527,939 ) bigcharts.marketwatch.com bigcharts.marketwatch.com Dec.9 was when it reported the results on Advexin on breast Ca patients, which showed a >50% reduction in tumor size in all of the patients, and that complete tumor removal by subsequent surgery was achieved in 100% of the patients. Those results were better than what would be expected from neoadjuvant chemotherapy treatment alone and there was some evidence of activation of a local immune response at the site of the tumor, since treated tumors were infiltrated with lymphocytes and that could be a sign that this "surgical pre-treatment" may be useful not only in controlling local disease, but in avoiding future metastases as well.<g> Bernard